X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
SIR-Spheres Y-90 resin microspheres is the first therapeutic radiopharmaceutical approved by the NMPA based on clinical trial data, for the treatment of patients with colorectal cancer liver metastases.
Lead Product(s): Yttrium Radioisotopes
Therapeutic Area: Oncology Product Name: SIR-Spheres Y-90
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Grand Pharmaceutical Group Limited
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 09, 2022
Details:
Through this agreement, Sirtex gains an option to non-exclusively co-promote the Company's lead product candidate, TAVO™ (tavokinogene telseplasmid) in anti-PD-1 checkpoint refractory metastatic melanoma in the U.S.
Lead Product(s): Tavokinogene Telseplasmid,Pembrolizumab
Therapeutic Area: Oncology Product Name: Tavo
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Recipient: OncoSec Immunotherapies
Deal Size: $30.0 million Upfront Cash: Undisclosed
Deal Type: Agreement January 19, 2021
Details:
Sirtex will support and assist OncoSec with pre-marketing activities for TAVO™ and its visceral lesion applicator (VLA) in exchange for low single-digit royalties on those products.
Lead Product(s): Tavokinogene Telseplasmid,Pembrolizumab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Recipient: OncoSec Immunotherapies
Deal Size: $30.0 million Upfront Cash: $30.0 million
Deal Type: Partnership February 10, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
